medigraphic.com
ISSN 1561-3186 (Electronic)

2009, Number 1

<< Back Next >>

Rev Acta Médica 2009; 12 (1)

Effectiveness of combined treatment with Molsidomine and Atenolol to high blood pressure control

del Pozo JHA, Leiva SLE, Gándara RA, Pérez PA

Language: Spanish
References: 24
Page:
PDF size: 204.77 Kb.


ABSTRACT

Introduction: The aim of present paper was to assess the antihypertensive effectiveness of Molsidomine, a vasodilator identified as direct donor of nitric oxide (NO) associated with low-doses of Atenolol compared to Atenolol as a monotherapy and also to identify the potential side effects.
Method: A double-blind controlled, clinical and randomized assay was carried out. Study sample included 50 patients assessed in the high blood pressure specialized consultation, which were distributed in two groups: Atenolol plus placebo (A group), and Atenolol plus Molsidomine (B Group) under a weekly control over four weeks increasing the dose according achieve tension control.
Results: Both therapeutical combinations showed its effectiveness to control the high blood pressure RR 0,95. Atenolol plus Molsidomine combination had an attributable improvement of 5% major. There were not significant adverse effects.
Conclusions: Molsidomine and Atenolol combination showed a greater antihypertensive effectiveness compared to Atenolol monotherapy, where the above mentioned improvement could be due to the nitric oxide (NO) effect on vascular endothelium suggesting that this drugs combination could to be of benefit for hypertensive patients presenting coexistent affections presenting a nitric oxide deficit. There were not significant side effects.


REFERENCES

  1. Hipertensión Arterial. Guía para la prevención, diagnóstico y tratamiento. 2008. Disponible en: http://bvs.sld.cu/libros_texto/hipertensión_arterial/completo.pdf.

  2. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure: The JNC-7 Report. JAMA. 2003; 289:(doi:10.1001/jama.289.19.2560).

  3. Laboratorios Hoechst, Información médica. Presse med, 1995, 24(6).

  4. Combis JM, Vinel JP, Badia P, Barange K, Payen JL, Combis F. Haemodynamic effects of molsidomine and propranolol in patients with cirrhosis. Br J Clin Pharmacol. 1996; 41 (5): 409-13.

  5. Banasiak W, Wilkins A, Pociupany R, Ponikowski P. Pharmacotherapy in patients with stable coronary artery disease treated on an outpatient basis in Poland. Results of the multicentre RECENT study. Kardiol Pol. 2008; 66(6): 642-9.

  6. Pérez Fernández GA, García Jacomino H, Reyes Hernández LM, Llanes Camacho MC. Nuevas consideraciones de aspectos clásicos del uso de betabloqueadores en la hipertensión arterial. MAPFRE MEDICINA. 2004; 15(2):141-7.

  7. Ong HT. B Blockers in hypertension and cardiovascular disease. Clinical Review BMJ. 2007; 334: 946-9.

  8. Cockroft JR. Preserve endothelium dependent vasodilatation in patients with essential hypertension. N Engl J Med. 1994; 330:1036-40.

  9. Loscalzo J. Nitric Oxide and vascular disease. N Engl J Med. 1995; 333(4):251-53.

  10. Panza JA. Endothelial dysfunction in essential hypertension. Clin Cardiol. 1997; 20(11 suppl 2):1126-1133.

  11. Cardillo C, Kilcoyne CM, Quyyumi AA, Canon RO, Panza JA. Selective defect in nitric oxide synthesis may explain the impaired endothelium-dependent vasodilatation in patients with essential hypertension. Circulation. 1998; 97(9): 851-6.

  12. Leiva L. Estrés oxidativo e hipertensión arterial esencial. Rev Cubana Med. 2000; 39 (1): 3-6.

  13. Leiva L, Pozo H, Pérez D. Óxido nítrico y su relación con la Hipertensión Arterial. Rev Cubana Med. 2000; 39 (3):174-8.

  14. Gail D Th, Weigno Zh, Ronald V. Nitric Oxide Deficiency as a cause of Clinical Hypertension. JAMA. 2001; Vol 286:2055-7.

  15. Jadraque LM, Mostaza JM. Disfunción endotelial y síndrome metabólico. Rev Esp Cardiol. 1998; 51(Supl 4):19-23.

  16. Zakharieva S. Arterial hypertension and obesity, a dangerous combination. Vutr Boles. 1999; 31(1):28-32.

  17. XXII Congress of the European Society of Cardiology. Amsterdam. August 26-30, 2000. Round Table focused on the role of arterial vascular endothelium in pathogenesis of atherosclerosis desease. Disponible en:http://www.athero.org.

  18. Sartori-Valinotti JC, Iliescu R, Fortepiani LA, Yanes LL, Reckelhoff JF. Sex differences in oxidative stress and the impact on blood pressure control and cardiovascular disease. Clin Exp Pharmacol Physiol. 2007; 34(9):938-45.

  19. Holvoet P. Relations between metabolic syndrome, oxidative stress and inflammation and cardiovascular disease. Verh K Acad Geneeskd Belg. 2008; 70(3):193-219.

  20. Carletti L, Rodríguez AN, Pérez AJ, Vasallo DV. Blood pressure response to physical exertion in adolescents: influence of overweight and obesity.Arq Bras Cardiol. 2008; 91(1):24-30.

  21. Altallaa Rached A, Estrada Saiz RV, Jaber Ismael A. Epidemiologic study of cardiovascular risk factors in Alcala de Henares, Madrid.An Med Interna. 1997; 14(5):226-30.

  22. Sitio Web en Internet. Disponible en:http://fcmfajardo.sld.cu/jornada/conferencias/tabaquismo/tabaquismo.htm.

  23. Duarte Noguera D. Capítulo 2. Sustancias provenientes de la combustión del tabaco. En: El hábito de fumar es nocivo a la salud. El tabaco enemigo público del ser humano. Editorial de la Universidad de Zulia, Maracaibo. 1991:17-36

  24. Daniel A. Popowich, Vinit Varu, Melinda R. Kibbe. Nitric Oxide: What a vascular Surgeon Needs to Know. Disponible en: http://www.medscape. com/viewarticle/569812




2020     |     www.medigraphic.com